A randomized prospective clinical trial of antilymphocyte globulin in 100 cadaveric renal transplants.
In controlled randomized study of antilymphocyte globulin (ALG) in 100 cadaveric renal transplants, 15 patients receiving a second transplant were excluded. Ofthe first transplants, 42 were in the control and 43 in the ALG group. The two groups were similar. The ALG used was either prodduced in our laboratories or obtained from a commerical source. It was observed that ALG produced a significant lymphopenia, that the oliguric phase of the ALG group was half that of the controls, and that the ALG group although less likely to suffer rejection episodes responded significantly better when treated than did those in the control group.
D000328:Adult; D000961:Antilymphocyte Serum / Q000009:adverse effects / Q000627:therapeutic use*; D002102:Cadaver; D002986:Clinical Trials as Topic; D006801:Humans; D007668:Kidney / Q000378:metabolism; D016030:Kidney Transplantation; D008231:Lymphopenia / Q000139:chemically induced; D008875:Middle Aged; D014181:Transplantation Immunology; D014184:Transplantation, Homologous
D000961:Antilymphocyte Serum